SEC Form 4 · accession 0001104659-18-072814
Y-mAbs Therapeutics, Inc. · YMAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Gad
Officer — President and Chairman · Director
Period of report
Dec 11, 2018
Accepted (ET)
Dec 13, 2018 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001722964
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $21.97 | Dec 11, 2018 | A | 107,500 | A | — | Dec 11, 2028 | Common Stock | 107,500 | 107,500 | D |
Explanation of responses
- F1The stock option shall vest and become exercisable as to 25% of the shares subject to the option on December 11, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.